Appears on
Articles10
GRAIL Update on the Accelerated Implementation of Multi-Cancer Early Detection Technology by NHS England
The NHS-Galleri trial, which started enrolling participants in 2021, was designed to inform implementation of the Galleri test as a national screening programme if recommended by the UK National Screening Committee on the basis of the final study results, which are expected in 2026. The trial was designed with three consecutive years of screening in […] Read
GRAIL Sponsored Industry Theater at ASCO 2024
View the presentation deck here. Read more at GRAIL
GRAIL stands with policymakers and stakeholders for Medicare access framework
We believe screening individuals for many types of cancer with a multi-cancer early detection (MCED) test represents a significant opportunity to reduce the burden of cancer. However, without Congressional action, Medicare beneficiaries and their doctors may face significant delays in accessing these innovative screening tests once they are FDA-approved. Led
GRAIL applauds policymakers’ commitment to MCED access
We believe screening individuals for many types of cancer with a multi-cancer early detection (MCED) test represents a significant opportunity to reduce the burden of cancer. Today, with a unanimous vote to advance the “Nancy Gardner Sewell Medicare Multi-Detection Early Detection Screening Coverage Act,” the House Committee on Ways and Means took an importa
Not All MCED Tests are Created Equal: The Realities of MCED Test Development and Validation
By Joshua Ofman MD, MSHS, GRAIL President; Megan P. Hall Ph.D., GRAIL Medical Affairs; Christina Clarke Dur Ph.D. GRAIL Cancer Epidemiology Multi-cancer early detection (MCED) tests hold enormous promise, but will only achieve their public health and clinical impact if the tests are validated rigorously in the appropriate “intended use” population: adults at
Making Sense of the Numbers: Interpreting Multi-Cancer Early Detection Test Performance
View the white paper here. Read more at GRAIL
PATHFINDER 2: What to Expect from the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Trial
Cancer screening has transformed outcomes for several cancers, but the vast majority of cancer deaths still occur in patients who have cancers without recommended screening tests. Multi-cancer early detection (MCED) tests can help address that gap. Rather than screening for one cancer at a time, the Galleri ® MCED test looks for a shared cancer signal […] Re
The NHS-Galleri trial: What to expect in 2026 from the world’s first randomized controlled trial of a Multi-Cancer Early Detection test, Galleri®
As the multi-cancer early detection (MCED) field evolves, we and others have asserted that it is essential – in order for individuals to have confidence in a test – that it must have demonstrated performance in a prospective trial in the intended use population ( Read more at GRAIL
Why Finding Cancers Before It’s Too Late Matters More Than Ever
The potential life-saving impact of reducing Stage IV disease and detecting more cancers at Stage III When people think about cancer screening, the emphasis is almost always on finding cancers as early as possible. That goal makes intuitive sense, but it can lead to an important oversight. The greatest threat to improving patient outcomes is […] Read more at
A Historic Moment in the Fight Against Cancer
Congress has taken a historic step forward in the fight against cancer. Thanks to the leadership of its bipartisan sponsors, and the work of advocates across the country, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act is now law following the President’s signature. Medicare will have an MCED benefit category, and along